4D Molecular Therapeutics

Overview

4D Molecular Therapeutics (NASDAQ: FORTH) is an American biotechnology company headquartered in Emeryville, California, focused on developing precision gene therapies using its proprietary adeno-associated virus (AAV) vector platform. Founded in 2012 by Dr. David Kirn and Dr. Charles Gersbach, 4DMT has raised over $740 million in funding and established strategic partnerships with major pharmaceutical companies["@d2026"].

Overview

4D Molecular Therapeutics (NASDAQ: FORTH) is an American biotechnology company headquartered in Emeryville, California, focused on developing precision gene therapies using its proprietary adeno-associated virus (AAV) vector platform. Founded in 2012 by Dr. David Kirn and Dr. Charles Gersbach, 4DMT has raised over $740 million in funding and established strategic partnerships with major pharmaceutical companies["@d2026"].

The company's name "4D" refers to its four-dimensional approach to vector engineering: considering tissue targeting, route of delivery, immune profile, and manufacturing scalability simultaneously. This sophisticated approach distinguishes 4DMT from traditional AAV development approaches that optimize for a single parameter["@kirn2019"].

Funding and Financial History

4DMT has demonstrated consistent growth through multiple funding rounds:

| Year | Event | Amount | Details |
|------|-------|--------|---------|
| 2014 | Series A | $10M | Initial seed funding for platform development |
| 2017 | Series B | $40M | Expanded R&D capabilities |
| 2019 | Series C | $95M | Advanced clinical programs |
| 2020 | Series D | $112M | Pre-IPO funding |
| 2021 | IPO | $168M | NASDAQ: FORTH |
| 2023 | Follow-on | $75M | Pipeline expansion |

The company maintains a strong financial position with a market capitalization of approximately $200 million as of 2025 and a cash runway extending into 2027[@d2026].

Company Details

| Attribute | Details |
|-----------|---------|
| Headquarters | Emeryville, California, USA |
| Founded | 2012 |
| Ticker | NASDAQ: FORTH |
| CEO | Dr. David Kirn |
| Market Cap | ~$200M (2025) |
| Employees | ~200 |
| Founded By | Dr. David Kirn, Dr. Charles Gersbach |

Technology Platform

RGD (Rational Vector Design) Platform

4DMT's proprietary RGD platform represents a sophisticated approach to AAV vector engineering that combines directed evolution, rational design, and high-throughput screening to develop optimized gene delivery vehicles[@kirn2019].

The platform enables:

• Directed evolution of AAV capsids for enhanced tissue tropism, creating variants that preferentially transduce target tissues while minimizing off-target effects
• High-throughput screening of millions of variants in relevant disease models, allowing rapid identification of lead candidates
• Rational design combining computational modeling with empirical testing, leveraging structural biology insights to guide optimization
• Immune evasion strategies to minimize pre-existing immunity and avoid neutralizing antibody recognition[@elandros2019]

Platform Advantages

4DMT's technology addresses key limitations of first-generation AAV vectors:

| Challenge | 4DMT Solution |
|-----------|---------------|
| Limited tissue tropism | Engineered capsids with enhanced target tissue transduction |
| Pre-existing immunity | Variants that evade neutralizing antibodies |
| Delivery route limitations | Vectors optimized for specific administration routes |
| Manufacturing scalability | Suspension cell culture production system |

Vector Engineering Approach

The company focuses on engineering AAV vectors with multiple optimized properties[@zincarelli2018]:

| Feature | Description |
|---------|-------------|
| Tissue specificity | Enhanced transduction of target tissues through engineered capsids |
| Route optimization | Vectors optimized for specific delivery routes (IV, intravitreal, inhalation) |
| Manufacturing scalability | Suspension cell culture production for commercial scale |
| Reduced immunogenicity | Evasion of neutralizing antibodies for repeat dosing |

Therapeutic Areas and Pipeline

Ophthalmology Programs

4DMT has developed a robust pipeline targeting retinal diseases[@calton2024]:

| Program | Target | Indication | Development Stage | Route |
|---------|--------|------------|-------------------|-------|
| 4D-150 | VEGF + Ang2 | Wet AMD | Phase 3 | Intravitreal |
| 4D-150 | VEGF | Diabetic Macular Edema (DME) | Phase 1/2 | Intravitreal |
| 4D-175 | Complement | Geographic Atrophy | Preclinical | Intravitreal |
| 4D-310 | GLA | Fabry Disease Cardiomyopathy | Phase 1/2 | Intravitreal |

4D-150 for Wet AMD

4D-150 is a dual-transgene intravitreal gene therapy for neovascular retinopathies. The Phase 1/2 trial demonstrated robust efficacy with patients maintaining vision gains at 12 months post-treatment[@calton2024]. The Phase 3 program is actively enrolling.

4D-310 for Fabry Disease

4D-310 delivers a functional copy of the GLA gene to treat Fabry disease cardiomyopathy, a genetic disorder caused by alpha-galactosidase A deficiency. The Phase 1/2 trial is evaluating safety and biomarker endpoints.

Pulmonology Programs

4DMT's aerosol delivery platform enables gene therapy for lung diseases[@calton2025]:

| Program | Target | Indication | Development Stage | Route |
|---------|--------|------------|-------------------|-------|
| 4D-710 | CFTR | Cystic Fibrosis | Phase 1/2 | Inhalation |
| 4D-725 | AAT | Alpha-1 antitrypsin deficiency | Preclinical | Inhalation |

4D-710 for Cystic Fibrosis

4D-710 is an aerosolized AAV gene therapy delivering a functional CFTR gene to lung epithelial cells. Preclinical data demonstrated significant CFTR expression in relevant cell types, and the Phase 1/2 trial is evaluating safety and efficacy[@calton2025].

CNS/Neurodegeneration Potential

While 4DMT has not yet advanced CNS programs into clinical development, the company has published research on brain delivery and maintains scientific capabilities in this area[@vadakkan2019][@meng2019].

Research Focus Areas

The company's CNS research focuses on:

• Blood-brain barrier penetration: Engineering vectors that cross the BBB through targeted evolution
• Astrocyte targeting: Delivery to supporting glial cells for metabolic support
• Neuronal transduction: Achieving therapeutic gene expression in neurons
• Microglia modulation: Targeting immune cells in the brain for neuroinflammatory disorders

Pipeline Potential

| Program | Target | Indication | Stage |
|---------|--------|------------|-------|
| 4D-C102 | CNS target | Alzheimer's disease | Discovery |
| 4D-C105 | Neuroinflammation | Parkinson's disease | Discovery |
| 4D-C110 | Tau pathology | Alzheimer's disease | Discovery |

4DMT's CNS programs remain in discovery, focusing on identifying optimal capsids for brain delivery and validating therapeutic targets for neurodegenerative diseases[@kotterman2014][@rayner2019].

Strategic Partnerships

4DMT has established partnerships with major pharmaceutical companies:

| Partner | Focus Area | Deal Value |
|---------|------------|------------|
| Pfizer | Pulmonary gene therapy | $250M+ |
| Roche | CNS programs | Via Spark acquisition |
| Novartis | Ophthalmic options | Option fees |
| Janssen | Retinal diseases | Development funding |

Pfizer Collaboration

The partnership with Pfizer focuses on developing AAV vectors for pulmonary diseases, leveraging 4DMT's RGD platform for targeted lung delivery. This collaboration validates the company's technology platform and provides non-dilutive funding for pipeline development.

Competition and Market Position

4DMT competes in the AAV gene therapy space:

| Company | Strengths | Weaknesses |
|---------|------------|------------|
| BioMarin | Approved gene therapies (Roctavian) | Limited CNS capability |
| Spark Therapeutics/Roche | Luxturna approved, global reach | Focus on ocular |
| uniQure | Hemgenix approval, manufacturing | Single product focus |
| Pfizer | Global reach, pipeline investment | In-house AAV development |
| Regenxbio | NAV vectors, multiple partnerships | Manufacturing challenges |
| Spark | First FDA-approved retinal gene therapy | Limited pipeline diversity |

4DMT's differentiation lies in its proprietary RGD platform, which enables systematic optimization of capsid properties for specific tissues and routes of delivery.

Leadership Team

• Dr. David Kirn: CEO and Co-founder, previously at Onyx Pharmaceuticals (acquired by Amgen), pioneer in AAV capsid engineering
• Dr. Charles Gersbach: Co-founder, Professor of Biomedical Engineering at Duke University
• Dr. R. Jude Samulski: Scientific Advisor, pioneer in AAV research and development
• Dr. Peter Francis: Chief Medical Officer, extensive ophthalmology clinical experience
• Dr. Melissa Kotterman: Chief Scientific Officer, expertise in directed evolution of AAV capsids

Scientific Publications

4DMT's research has been published in leading peer-reviewed journals:

Future Directions

4DMT's pipeline expansion strategy includes:

• Additional ocular indications: Exploring dry AMD, diabetic retinopathy, and inherited retinal dystrophies
• Additional pulmonary targets: COPD, asthma, and other lung diseases
• CNS expansion: Alzheimer's, Parkinson's, and other neurodegenerative disorders (pending partnership)
• Platform extensions: Novel capsids, promoters, and regulatory elements

Cross-References

• [Gene Therapy](/treatments/gene-therapy)
• [AAV Vectors](/mechanisms/aav-vectors)
• [Alzheimer's Disease](/diseases/alzheimers-disease) - potential applications
• [Parkinson's Disease](/diseases/parkinsons-disease) - potential applications
• [Neurodegeneration](/diseases/neurodegeneration)
• [Biogen](/companies/biogen)
• [Roche](/companies/roche)
• [Pfizer](/companies/pfizer)
• [Denali Therapeutics](/companies/denali)
• [ uniQure](/companies/uniqure)

External Links

• [4DMT Official Website](https://www.4dmt.com)
• [Pipeline Information](https://www.4dmt.com/pipeline/)
• [SEC Filings](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001783232)
• [Google Scholar - 4DMT Publications](https://scholar.google.com/scholar?q=4D+Molecular+Therapeutics)